Valsartan Tablets 160 mg USP, 90 tablet bottles, Rx only, Distributed by: Acetris Health, LLC, Sa...
FDA Drug Recall #D-1054-2019 — Class II — March 7, 2019
Recall Summary
| Recall Number | D-1054-2019 |
| Classification | Class II — Moderate risk |
| Date Initiated | March 7, 2019 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Rising Pharmaceuticals, Inc. |
| Location | Saddle Brook, NJ |
| Product Type | Drugs |
| Quantity | 35,281 bottles |
Product Description
Valsartan Tablets 160 mg USP, 90 tablet bottles, Rx only, Distributed by: Acetris Health, LLC, Saddle Brook, NJ 07663, Manufactured by: Aurolife Pharma LLC, Dayton, NJ 08810 ---- NDC 52343-124-90
Reason for Recall
CGMP Deviations; Detection of a trace amount of unexpected impurity N- nitrosodiethylamine (NDEA) found in finished products
Distribution Pattern
Product was distributed to 6 major distributors who may have further distributed the product throughout the United States.
Lot / Code Information
472180005B, exp. date 02/29/2020 472180011A, exp. date 04/30/2020 472180012A, exp. date 04/30/2020
Other Recalls from Rising Pharmaceuticals, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-1367-2020 | Class III | Timolol Maleate USP, 0.5%, 5 mL, Sterile Optha... | Nov 15, 2019 |
| D-1368-2020 | Class III | Timolol Maleate Sterile Opthalmic Solution,USP ... | Nov 15, 2019 |
| D-1052-2019 | Class II | Valsartan Tablets 40 mg USP, 30 tablet bottles,... | Mar 7, 2019 |
| D-1055-2019 | Class II | Valsartan Tablets 320 mg USP, 90 tablet bottles... | Mar 7, 2019 |
| D-1053-2019 | Class II | Valsartan Tablets 80 mg USP, 90 tablet bottles,... | Mar 7, 2019 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.